Log in

Relevant bibliographies by topics / 343.148 (477)(043.2) / Journal articles

To see the other types of publications on this topic, follow the link: 343.148 (477)(043.2).

Journal articles on the topic '343.148 (477)(043.2)'

Author: Grafiati

Published: 30 May 2022

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic '343.148 (477)(043.2).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Yousuf, Muhammad, Ayalew Tefferi, Naseema Gangat, et al. "Hydroxyurea vs. hypomethylating vs. other agents in chronic myelomonocytic leukemia: A retrospective inspection of treatment strategies among 457 Mayo Clinic patients." Journal of Clinical Oncology 43, no. 16_suppl (2025): 6579. https://doi.org/10.1200/jco.2025.43.16_suppl.6579.

Full text

Abstract:

6579 Background: Treatment strategies in chronic myelomonocytic leukemia (CMML) are not standardized and include hydroxyurea (HU) and hypomethylating agents (HMA). In a phase 3 study comparing HU and decitabine, in proliferative CMML, response rates were higher for decitabine (56% vs 31%; p<0.01) but overall survival was similar (p=0.67) between the two groups (Itzykson, R. JCO, 2023. 41:1888). In the current retrospective study, we examined the survival impact of different treatment strategies among 457 Mayo Clinic patients with CMML. Methods: The current study was conducted under institut

APA, Harvard, Vancouver, ISO, and other styles

2

Dombret, Hervé, Alexandra Coelho, Laurène Fenwarth, et al. "Treatments and Outcomes of Adult Patients with AML in the Real-Life - First Report of the French Observational ALFA-PPP Study." Blood 144, Supplement 1 (2024): 2424. https://doi.org/10.1182/blood-2024-207226.

Full text

Abstract:

Introduction. AML treatment options have been recently enriched. New agents like gemtuzumab ozogamicin (GO), FLT3 or IDH inhibitors, or CPX-351 have been approved for some patient subsets. Less-intensive options, like the AZA-VEN combination, are used in older/unfit patients. However, while treatments and indications are standardized, their choice is not, depending on often-subjective factors. This makes observational studies so important to describe the real-life management and outcomes of AML patients. Methods. In 2022, the ALFA group initiated a 2-cohort (newly diagnosed, relapsed/refractor

APA, Harvard, Vancouver, ISO, and other styles

3

Liao, Wei, Matthew Paul Smeltzer, Jordan Goss, et al. "Lung cancer diagnosis rates (LCDR) in lung cancer screening (LCS) and incidental pulmonary nodule (IPN) cohorts in the Mississippi Delta." Journal of Clinical Oncology 43, no. 16_suppl (2025): 8002. https://doi.org/10.1200/jco.2025.43.16_suppl.8002.

Full text

Abstract:

8002 Background: The LCDR in the CT screened cohort in the National Lung Screening Trial (NLST) was 1.1% over a median of 6.5 years follow up. We evaluated the LCDR in a regional US community. Methods: Prospective cohort study of patients in LCS and IPN programs in 22 facilities across a 125 county service area population. We compared LCDR over 3 years in LCS stratified by Lung-RADS (L-R) score (1 to 4X), IPN by nodule size (≤6, >6-15, >15-20, >20-30 mm) on initial CT scans. Comparisons used Chi-square tests, Wilcoxon tests, and Cox regression models with Hazard Ratios (HR) for lung c

APA, Harvard, Vancouver, ISO, and other styles

4

Musso Ribeiro de Oliveira Souza, Chiara, Gustavo Ribeiro Lima, and Angélica Espinosa Miranda. "Blood-borne infections and pregnancies among women attending a sexual violence assistance center in Brazil: A 10-year retrospective study." PLOS ONE 18, no. 2 (2023): e0280419. http://dx.doi.org/10.1371/journal.pone.0280419.

Full text

Abstract:

Introduction Sexually transmitted infections (STI) and pregnancy can be consequences of sexual violence. In Brazil, around 50% of women victims of sexual violence do not undergo STI prophylaxis or emergency contraception. Objectives To analyze socio-demographic and epidemiological profile, frequency of procedures performed, frequency of blood-borne infections (BBI), pregnancy, and legal abortion in women assisted by a sexual violence assistance center. Patients and methods This 10-year retrospective cohort study (2010–2019) describes the socio-demographic and epidemiological profile and freque

APA, Harvard, Vancouver, ISO, and other styles

5

Teshima, Takanori, K. Matsuo, K. Matsue, et al. "Impact of HLA Mismatch on the Incidence of Acute GVHD and Rejection after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation (RICT)." Blood 104, no. 11 (2004): 2758. http://dx.doi.org/10.1182/blood.v104.11.2758.2758.

Full text

Abstract:

Abstract HLA incompatibility between the donor and recipient is the most critical factor governing the incidence of rejection and GVHD after conventional allogeneic stem cell transplantation. But the impact of HLA disparity on GVHD and graft rejection after RICT remains to be elucidated. We retrospectively analyzed the outcomes of 437 patients who underwent bone marrow (n=95) or peripheral blood stem cell RICT (n=342). The numbers of patients who received a graft from a HLA-matched (275 from siblings, 11 from family members, and 54 from unrelated donors), one-locus-mismatched, 2- or 3-loci-mis

APA, Harvard, Vancouver, ISO, and other styles

6

Tan, Juanyi, Szu-Chun Yang, Michaela A. Dinan, Anne C. Chiang, Cary P. Gross, and Shi-Yi Wang. "Biomarker-Specific Survival and Medication Cost for Patients With Non–Small Cell Lung Cancer." JAMA Network Open 8, no. 6 (2025): e2514519. https://doi.org/10.1001/jamanetworkopen.2025.14519.

Full text

Abstract:

ImportanceTargeted therapies and immunotherapies prolong survival but are associated with high costs for patients with advanced non–small cell lung cancer (aNSCLC). To date, little is known about survival and medication cost by biomarker status in the US.ObjectiveTo estimate survival and medication cost by aNSCLC biomarker status.Design, Setting, and ParticipantsThis retrospective cohort study using Flatiron Health data identified patients diagnosed with aNSCLC from January 1, 2016, through December 31, 2022. Each patient had received at least 1 biomarker test and 1 documented line of therapy;

APA, Harvard, Vancouver, ISO, and other styles

7

Radchenko, Elena V., Olga A. Sykhovskaya, Timofey L. Galankin, Aleksei S. Kolbin, and Maria A. Smirnova. "Network meta-analysis: a comparison of effectiveness and safety of partial agonists of nicotinic acetylcholine receptors varenicline and cytisine for smoking cessation." Reviews on Clinical Pharmacology and Drug Therapy 16, no. 4 (2018): 19–32. http://dx.doi.org/10.17816/rcf16419-32.

Full text

Abstract:

Background. Partial agonists of α4b2 nicotinic acetylcholine receptors are the most effective treatment strategy for tobacco smoking cessation. They are able to alleviate withdrawal symptoms and to reduce smoking satisfaction. The aim of this study was to review the efficacy and safety of nicotinic receptor partial agonists varenicline and cytisine, for smoking cessation. Methods. A search for randomized controlled trials was done using the terms (“cytisine”, “tabex”, “varenicline” or 'partial agonists of nicotinic receptors’) in MEDLINE, EMBASE, eLibrary in May 2018. Types of part

APA, Harvard, Vancouver, ISO, and other styles

8

Biswas, Sourav, Zeba Khanam, Asraful Alam, and Lakshminarayan Satpati. "Progress and determinants of household access to improved drinking water in India using a Water Access Index: insights from the National Family Health Survey towards achieving SDG 6.1." BMJ Open 15, no. 6 (2025): e091269. https://doi.org/10.1136/bmjopen-2024-091269.

Full text

Abstract:

Background and objectiveAccess to clean drinking water is essential for health and development. Despite global and national initiatives, many regions in India continue to face inadequate water access. This study assesses progress, sociodemographic determinants and geographic disparities in access to drinking water in India, aligning with Sustainable Development Goal (SDG) 6.1.DesignThis study used secondary data from five rounds of the National Family Health Survey (NFHS-1 to NFHS-5; 1992–2021), nationally representative surveys conducted across India. Logistic regression was employed to exami

APA, Harvard, Vancouver, ISO, and other styles

9

Vadhan-Raj, Saroj, Naomi V. Dahl, Kristine Bernard, Zhu Li, and William Strauss. "Efficacy and Safety of IV Ferumoxytol (FER) for Iron Deficiency Anemia (IDA) in Patients with Cancer." Blood 124, no. 21 (2014): 1352. http://dx.doi.org/10.1182/blood.v124.21.1352.1352.

Full text

Abstract:

Abstract Background: IDA is common in cancer patients due to blood loss and inflammation. Many do not tolerate oral iron or adequately respond. Two Phase-3 trials investigated the efficacy and safety of IV FER for treatment of IDA in patients with a history of unsatisfactory oral iron therapy or in whom oral iron could not be used. This analysis explored the impact of IV iron treatment on the subgroup of patients with cancer. Methods: Data from patients with cancer were extracted from 2 RCTs (NCT01114139; NCT01114204) in which patients with baseline (BL) Hgb 7-10g/dL, TSAT <20%, were random

APA, Harvard, Vancouver, ISO, and other styles

10

Zhong, Runbo, Min Yan, Qiming Wang, et al. "Phase 1 trial of SHR-A2102, a nectin-4–directed antibody drug conjugate (ADC), in advanced solid tumors." Journal of Clinical Oncology 43, no. 16_suppl (2025): 107. https://doi.org/10.1200/jco.2025.43.16_suppl.107.

Full text

Abstract:

107 Background: Nectin-4 is a cell adhesion molecule that is highly expressed in a wide variety of cancers and is associated with poor prognosis. SHR-A2102 is a novel ADC consisting of a fully humanized Nectin-4–directed monoclonal antibody, bound to topoisomerase I inhibitor payload via a cleavable linker. We conducted a multi-center, phase 1 trial to evaluate SHR-A2102 in advanced solid tumors. Methods: Patients (pts) with Nectin-4 positive, locally advanced unresectable or metastatic solid tumors were enrolled. The study included dose-escalation (D-ESC), dose-expansion (D-EXP) and efficacy-

APA, Harvard, Vancouver, ISO, and other styles

11

Van der Heijde, D., L. S. Gensler, A. Deodhar, et al. "OP0105 EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 68–69. http://dx.doi.org/10.1136/annrheumdis-2020-eular.323.

Full text

Abstract:

Background:Bimekizumab (BKZ), a monoclonal antibody that selectively neutralises interleukin (IL)-17A and IL-17F, is a potential therapeutic option in ankylosing spondylitis (AS).Objectives:To report 48-week (wk) patient-reported outcomes (PROs) in patients (pts) with AS treated with BKZ in a phase 2b dose-ranging study (BE-AGILE;NCT02963506).Methods:Pts with active AS (Bath AS Disease Activity Index [BASDAI] ≥4; spinal pain ≥4 [0–10]), fulfilling modified New York criteria (central reading), and inadequate response/intolerance to NSAIDs were randomised according to the study design (Figure 1)

APA, Harvard, Vancouver, ISO, and other styles

12

Marincowitz, Carl, Omar Bouamra, Tim Coates, et al. "1427 The effect of the COVID-19 pandemic on major trauma presentations and patient outcomes in English hospitals." Emergency Medicine Journal 39, no. 12 (2022): A960.2—A964. http://dx.doi.org/10.1136/emermed-2022-rcem2.2.

Full text

Abstract:

Aims, Objectives and BackgroundThere is evidence that COVID-19 ‘lockdowns’ may have contributed to increased non-accidental injury, domestic violence and self-harm related to deteriorating mental health. Internationally, there is also evidence that the diversion of health care resources may led to worse outcomes for patients presenting with major trauma. There has been no previous national evaluation of ‘lockdown’ measures impact on the characteristics, treatment pathways and outcomes of trauma patients in EnglandWe aimed to assess the impact of successive lockdowns on the volume, demographics

APA, Harvard, Vancouver, ISO, and other styles

13

Park, Junghyun, and Marc Rodger. "Retrospective Cohort of Unprovoked Venous Thromboembolism Patients: What Proportion Have Potent Thrombophilias Necessitating Indefinite Anticoagulants?" Blood 126, no. 23 (2015): 2318. http://dx.doi.org/10.1182/blood.v126.23.2318.2318.

Full text

Abstract:

Introduction Thrombophilia testing in unprovoked venous thromboembolism patients (VTE) is controversial. Common thrombophilias such as Factor V Leiden or prothrombin gene variant appear to not importantly increase the risk of VTE recurrence, and thus are not considered in anticoagulation management decisions. However, patients with potent thrombophilias such as antiphospholipid antibodies (APLA), antithrombin deficiency, protein C and S deficiency, and homozygous genetic thrombophilias or combined defects are at higher risk of recurrence and it is recommended that they receive long-term antico

APA, Harvard, Vancouver, ISO, and other styles

14

Alpizar-Rodriguez, D., F. Irazoque-Palazuelos, T. S. Rodriguez-Reyne, et al. "POS1242 FACTORS ASSOCIATED WITH MORTALITY IN PATIENTS WITH RHEUMATIC DISEASES AND COVID-19 IN MEXICO." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 904.1–904. http://dx.doi.org/10.1136/annrheumdis-2021-eular.3342.

Full text

Abstract:

Background:As of the 25th of January 2021, more than 150 thousand deaths as consequence of COVID-19 have been reported in Mexico [1]. Advanced age, male gender and comorbidities have been described as risk factors for severe disease and mortality in general population [2]. COVID-19 mortality in Mexican patients with rheumatic and musculoskeletal diseases (RMDs) is unknown.Objectives:To describe characteristics of Mexican patients with RMDs and COVID-19, and to analyse factors associated with mortality.Methods:The Global Rheumatology Alliance COVID-19 (GRA) physician reported registry, is an in

APA, Harvard, Vancouver, ISO, and other styles

15

Rodríguez Salas, G., A. M. Santos, V. Navarro-Compán, et al. "AB1023 THE DIFFERENTIAL CHARACTERISTIC OF SPONDYLOARTHRITIS PATIENTS WHO CANNOT BE CLASSIFIED ACCORDING TO ASAS: RESULTS FROM THE GESPA COLOMBIAN COHORT." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1733.2–1734. http://dx.doi.org/10.1136/annrheumdis-2023-eular.5271.

Full text

Abstract:

BackgroundThe Assessment of SpondyloArthritis International Society (ASAS) classification criteria for SpA has changed the approach to the disease, enhancing the performance of the classification process. However, regardless of the ASAS classification criteria were developed according to a global cohort of patients, Latin American patients were not included in a significant number. SpA patients from our region have unique characteristics that may impact the SpA classification. Other alleles than HLA-B27 have been identified, the frequency of HLA-B15 was reported to be 19.1% in the Latin Americ

APA, Harvard, Vancouver, ISO, and other styles

16

Wadenvik, H., J. Kutti, B. Ridell, et al. "The effect of alpha-interferon on bone marrow megakaryocytes and platelet production rate in essential thrombocythemia." Blood 77, no. 10 (1991): 2103–8. http://dx.doi.org/10.1182/blood.v77.10.2103.2103.

Full text

Abstract:

Abstract In 10 patients with previously untreated essential thrombocythemia (ET), by using 111In-labeled platelets and megakaryocyte morphometry, the relation between platelet production rate and bone marrow megakaryocytes was evaluated before and during alpha-2b-interferon (IFN) therapy. A highly significant decrease in platelet count occurred during IFN therapy; the platelet counts, at baseline and after 2 and 6 months of IFN therapy, were 1,102 +/- 345 x 10(9)/L, 524 +/- 169 x 10(9)/L (P less than .0001), and 476 +/- 139 x 10(9)/L (P less than .0001), respectively. The decrement in platelet

APA, Harvard, Vancouver, ISO, and other styles

17

Wadenvik, H., J. Kutti, B. Ridell, et al. "The effect of alpha-interferon on bone marrow megakaryocytes and platelet production rate in essential thrombocythemia." Blood 77, no. 10 (1991): 2103–8. http://dx.doi.org/10.1182/blood.v77.10.2103.bloodjournal77102103.

Full text

Abstract:

In 10 patients with previously untreated essential thrombocythemia (ET), by using 111In-labeled platelets and megakaryocyte morphometry, the relation between platelet production rate and bone marrow megakaryocytes was evaluated before and during alpha-2b-interferon (IFN) therapy. A highly significant decrease in platelet count occurred during IFN therapy; the platelet counts, at baseline and after 2 and 6 months of IFN therapy, were 1,102 +/- 345 x 10(9)/L, 524 +/- 169 x 10(9)/L (P less than .0001), and 476 +/- 139 x 10(9)/L (P less than .0001), respectively. The decrement in platelet count wa

APA, Harvard, Vancouver, ISO, and other styles

18

Gomes, Tiago Halyson de Oliveira, Beatriz Pellizzon, Giovanna Victória Moura Araújo, et al. "MAMOPLASTIA PÓS BARIÁTRICA." Revista ft 29, no. 144 (2025): 02–03. https://doi.org/10.69849/revistaft/fa10202503150102.

Full text

Abstract:

INTRODUÇÃO: A mamoplastia pós bariátrica é um procedimento cirúrgico realizado para remodelar as mamas de pacientes que passaram por cirurgia bariátrica, visando corrigir a flacidez e o excesso de pele resultantes da perda significativa de peso. Esse procedimento é indicado para melhorar a estética e a autoestima dos pacientes, após a redução substancial de peso corporal. OBJETIVOS: O objetivo do presente trabalho foi realizar o levantamento acerca dos procedimentos cirúrgicos de mamoplastia pós bariátrica no Brasil, entre o período de 2013 a 2024. METODOLOGIA: O presente estudo trata-se de um

APA, Harvard, Vancouver, ISO, and other styles

19

Wada, Eri, Takeshi Onoue, Tomoko Kobayashi, et al. "Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial." BMJ Open Diabetes Research & Care 8, no. 1 (2020): e001115. http://dx.doi.org/10.1136/bmjdrc-2019-001115.

Full text

Abstract:

IntroductionThe present study aimed to evaluate the effects of flash glucose monitoring (FGM) and conventional self-monitoring of blood glucose (SMBG) on glycemic control in patients with non-insulin-treated type 2 diabetes.Research design and methodsIn this 24-week, multicenter, open-label, randomized (1:1), parallel-group study, patients with non-insulin-treated type 2 diabetes at five hospitals in Japan were randomly assigned to the FGM (n=49) or SMBG (n=51) groups and were provided each device for 12 weeks. The primary outcome was change in glycated hemoglobin (HbA1c) level, and was compar

APA, Harvard, Vancouver, ISO, and other styles

20

Wong, Vanessa, Wei Hong, Sumitra Ananda, et al. "Options beyond BRAF targeted therapy in second-line treatment of patients with BRAFV600E mutant (BRAFmt) metastatic colorectal cancer (mCRC)." Journal of Clinical Oncology 40, no. 4_suppl (2022): 47. http://dx.doi.org/10.1200/jco.2022.40.4_suppl.047.

Full text

Abstract:

47 Background: BRAFmt is a negative prognostic factor in mCRC but also identifies a patient population that may benefit from BRAF targeted therapy. Results from recent trials (BEACON and SWOG1406) demonstrate improved survival outcomes in second- and third-line settings when combining a BRAF inhibitor, an EGFR inhibitor (EGFRi) +/- a MEK inhibitor. In both trials, irinotecan and cetuximab was the control arm with a dismal response rate of 2-4% and progression free survival (PFS) of only 2 months. This suggests chemotherapy plus an EGFRi may not be the optimal approach where BRAF-targeted thera

APA, Harvard, Vancouver, ISO, and other styles

21

Hernández-Cruz, B., M. J. Miranda García, J. Barrera, et al. "AB1030 PATIENT CARE AT THE FRACTURE LIAISON SERVICE REDUCE THE GAP IN THE TREATMENT OF OSTEOPOROSIS BETWEEN MEN AND WOMEN." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1638–39. http://dx.doi.org/10.1136/annrheumdis-2022-eular.4150.

Full text

Abstract:

BackgroundOsteoporosis (OP) between men and women is different,and the way it is treated also differs. In men, the gap in clinical care, especially diagnosis and treatment, is worse.ObjectivesTo analyze the differences in the clinical characteristics of OP (demographics, comorbidities, diagnosis, and treatment) in an gold star Fracture Liaison Service (FLS).MethodsDesign: Observational, prospective, analytical study of usual clinical practice. All patients treated from an FLS from May 2018 to August 2021 were prospectively included. Of each patient, 160 clinical variables were introduced in a

APA, Harvard, Vancouver, ISO, and other styles

22

Greenberg, P., G. Dine, A. Ganser, et al. "Deferasirox (Exjade®, ICL670) Demonstrates Dose-Related Effects on Body Iron Levels Related to Transfusional Iron Intake in Transfusion-Dependent Anemia." Blood 106, no. 11 (2005): 2694. http://dx.doi.org/10.1182/blood.v106.11.2694.2694.

Full text

Abstract:

Abstract Iron overload, a potentially serious consequence of multiple blood transfusions, can be effectively managed with chelation therapy. Deferasirox, an investigational once-daily oral chelator, has been evaluated in a 1 year study of iron-overloaded adult and pediatric patients (n=184) with transfusion-dependent anemia including β-thalassemia, myelodysplastic syndromes (MDS) and Diamond-Blackfan anemia (DBA). Patients were stratified into four daily dose groups (5, 10, 20 and 30 mg/kg) according to baseline liver iron concentration (LIC; 2–3, &gt;3–7, &gt;7–14 and &gt;14 mg Fe

APA, Harvard, Vancouver, ISO, and other styles

23

Shtakal, M. I., L. P. Kolomiiets, L. M. Holyk, V. M. Shtakal, N. V. Hopkalo, and N. V. Ivashchenko. "Prospectivity of use of medicinal and feed grass for production of organic feed additives for animal feeding." Agriculture and plant sciences: theory and practice, no. 1 (May 16, 2022): 34–40. http://dx.doi.org/10.54651/agri.2022.01.04.

Full text

Abstract:

Goal. Establish the most productive types of medicinal and forage grasses for the formation of phyto-mixtures based on them to obtain organic feed additives for animal feed. Methods. Field, laboratory, animal testing by group method, means of variation statistics. Results. On the basis of the conducted researches the optimum terms of collecting of medicinal and forage grasses are established. According to the yield of dry mass, the most productive are milk thistle (3.6–4.2 t / ha), еchinacea purpurea (3.3–4.7 t / ha), fennel (3.0–4.0 t / ha) and the Moldavian snakehead (2.8–4.3 t / ha), and by

APA, Harvard, Vancouver, ISO, and other styles

24

He, Xin, Kyriakie Sarafoglou, Patricia Y. Fechner, et al. "Changes in Adrenal and Gonadal Androgens After 14-Day Treatment With CRF1 Receptor Antagonist, Crinecerfont (NBI-74788), in Men With Classic 21-Hydroxylase Deficiency." Journal of the Endocrine Society 5, Supplement_1 (2021): A78. http://dx.doi.org/10.1210/jendso/bvab048.157.

Full text

Abstract:

Abstract Background: Congenital adrenal hyperplasia due to classic 21-hydroxylase deficiency (21OHD) causes cortisol insufficiency and androgen excess. A phase 2 trial of crinecerfont, a CRF1 receptor antagonist, in 18 adults with 21OHD showed prominent decreases in ACTH, 17-hydroxyprogesterone, and androstenedione (A4), and in women, testosterone (T), after 14 days of treatment. In men with 21OHD, T derives from both adrenals and testes; in poor disease control, A4/T ratio is elevated due to disproportionately increased adrenal A4 production and decreased testicular T production. We sought to

APA, Harvard, Vancouver, ISO, and other styles

25

Bizino, Maurice B., Ingrid M. Jazet, Paul de Heer, et al. "Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation." Diabetologia 63, no. 1 (2019): 65–74. http://dx.doi.org/10.1007/s00125-019-05021-6.

Full text

Abstract:

Abstract Aims/hypothesis The aim of this work was to assess the effect of liraglutide on ectopic fat accumulation in individuals with type 2 diabetes mellitus. Methods This study is a pre-specified subanalysis of the MAGNetic resonance Assessment of VICTOza efficacy in the Regression of cardiovascular dysfunction In type 2 diAbetes mellitus (MAGNA VICTORIA) study, with primary endpoints being the effects of liraglutide on left ventricular diastolic and systolic function. The MAGNA VICTORIA study was a single-centre, parallel-group trial in 50 individuals with type 2 diabetes mellitus (BMI >

APA, Harvard, Vancouver, ISO, and other styles

26

Sagakyants, Aleksandr B., Elena S. Bondarenko, Darya Yu Yakubova, et al. "Amount of cancer stem cells in tumors of patients with ovarian cancer with different responses to platinum-containing chemotherapy." Journal of Clinical Oncology 39, no. 15_suppl (2021): e17527-e17527. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e17527.

Full text

Abstract:

e17527 Background: Resistance to chemotherapy is a complex problem in the treatment of patients with ovarian cancer (OC), and this phenomenon is associated, among other things, with the presence of cancer stem cells (CSCs). The purpose of the study was to determine the amount of CSCs in tumors of OC patients with different responses to chemotherapy they receive. Methods: Samples of ovarian tumors were obtained from 100 patients (aged 29-79 years) with advanced ovarian cancer stage IIIC-IV with/without ascites. All patients recruited in 2016-2020 received standard combination treatment with sur

APA, Harvard, Vancouver, ISO, and other styles

27

Herndon, Andrea K., Jessica M. Quimby, Liberty G. Sieberg, et al. "Preliminary pharmacokinetics of intravenous and subcutaneous dolasetron and pharmacodynamics of subcutaneous dolasetron in healthy cats." Journal of Feline Medicine and Surgery 20, no. 8 (2017): 721–27. http://dx.doi.org/10.1177/1098612x17729310.

Full text

Abstract:

Objectives The objectives were to evaluate the pharmacokinetics (PK) of subcutaneous (SC) and intravenous (IV) dolasetron and the pharmacodynamics (PD) of SC dolasetron in healthy cats. Methods Five cats with unremarkable complete blood count, serum biochemistry and urinalyses were utilized. In the PK study, cats received 0.8 mg/kg SC and IV dolasetron in a crossover format. Serum samples were obtained via a jugular catheter at 0, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 36 and 48 h after the administration of dolasetron. Dolasetron and the active metabolite hydrodolasetron were measured using liquid ch

APA, Harvard, Vancouver, ISO, and other styles

28

Magrey, M., M. G. H. Van de Sande, M. Breban, et al. "POS1107 BIMEKIZUMAB ACHIEVED SUSTAINED IMPROVEMENTS IN EFFICACY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, REGARDLESS OF PRIOR TNF INHIBITOR TREATMENT: WEEK 52 POOLED RESULTS FROM TWO PHASE 3 STUDIES." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 876–77. http://dx.doi.org/10.1136/annrheumdis-2023-eular.836.

Full text

Abstract:

BackgroundIn patients (pts) with axial spondyloarthritis (axSpA), tumour necrosis factor inhibitors (TNFi) are the usual first line biologic treatment, yet many pts may experience loss of response over time, and some are intolerant to TNFis.[1]Typically, response to second line biologics is limited in TNFi-inadequate responders (IR).Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. In the phase 3 BE MOBILE 1 and 2 studies, BKZ treatment resulted in rapid and sustained improvements in efficacy outcomes through 52 weeks (wks) in pts with acti

APA, Harvard, Vancouver, ISO, and other styles

29

Zhang, X., H. Huang, Y. Fan, and Z. Zhang. "AB0533 EFFECT OF RENIN-ANGIOTENSIN SYSTEM INHIBITORS ON RENAL REMISSION IN LUPUS NEPHRITIS: A REAL-WORLD SINGLE-CENTER STUDY." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1465.1–1465. http://dx.doi.org/10.1136/annrheumdis-2023-eular.4162.

Full text

Abstract:

BackgroundRenin-angiotensin-system inhibitors (RASi) reduce urinary protein excretion and protect renal function in both diabetic and nondiabetic nephropathy. Few studies have focused on RASi in LN patients.ObjectivesThe study aimed to provide real-world evidence to assess the effect of RASi in LN patients.MethodsA total of 233 LN patients were included; 155 were RASi users, and 78 were not. The rate of proteinuria partial recovery (PPR), complete remission (CR), total remission (TR), the decline and decline rate of proteinuria at 6 and 12 months were compared by Chi-square test and Kaplan‒Mei

APA, Harvard, Vancouver, ISO, and other styles

30

Bottinor, Wendy, Haoxue Xiang, Yan Chen, et al. "Cardiovascular risk factor severity and adverse cardiovascular events: A report from the Childhood Cancer Survivor Study (CCSS)." Journal of Clinical Oncology 43, no. 16_suppl (2025): 12055. https://doi.org/10.1200/jco.2025.43.16_suppl.12055.

Full text

Abstract:

12055 Background: Among survivors of childhood cancer, more severe grades of CVRFs are associated with increased risk for adverse cardiovascular events (ACE). The impact of low severity CVRFs has not been defined. Methods: Among 25,723 long-term survivors of childhood cancer, CVRF severity was graded using longitudinal self-report: Grade 1 conditions are reported but not on medications; Grade 2 are prescribed medications. Cumulative incidence of CVRFs were estimated into the 6 th decade of life with death and Grade 2 CVRFs a competing risk event for Grade 1 CVRFs. Starting at 1st report of a C

APA, Harvard, Vancouver, ISO, and other styles

31

Itzykson, Raphael, Elise Fournier, Céline Berthon, et al. "Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy." Blood 138, no. 7 (2021): 507–19. http://dx.doi.org/10.1182/blood.2021011103.

Full text

Abstract:

Abstract To design a simple and reproducible classifier predicting the overall survival (OS) of patients with acute myeloid leukemia (AML) ≥60 years of age treated with 7 + 3, we sequenced 37 genes in 471 patients from the ALFA1200 (Acute Leukemia French Association) study (median age, 68 years). Mutation patterns and OS differed between the 84 patients with poor-risk cytogenetics and the 387 patients with good (n = 13), intermediate (n = 339), or unmeasured (n = 35) cytogenetic risk. TP53 (hazards ratio [HR], 2.49; P = .0003) and KRAS (HR, 3.60; P = .001) mutations independently worsened the

APA, Harvard, Vancouver, ISO, and other styles

32

Nakayama, Y., R. Nakashima, T. Handa, et al. "POS1051 LUNG CLUSTERING ANALYSIS-BASED PHENOTYPES OF RHEUMATOID ARTHRITIS USING ARTIFICIAL INTELLIGENCE-BASED TECHNOLOGY FOR CHEST COMPUTED TOMOGRAPHY." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 843.1–844. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2178.

Full text

Abstract:

BackgroundLung involvement is a prevalent extraarticular manifestation of rheumatoid arthritis (RA) that remains a significant clinical challenge. Few studies have comprehensively quantified lung abnormalities of RA patients using artificial intelligence-based (AI) technology.ObjectivesThe aim of this study was to quantify lung lesions in RA patients and classify them based on their lung parameters.MethodsAn AI-based quantitative computed tomography (CT) image analysis software (AIQCT) was applied to high-resolution CT scans of RA patients in a cross-sectional manner. AIQCT automatically class

APA, Harvard, Vancouver, ISO, and other styles

33

Michallet, Mauricette, Mohamad Sobh, Stephane Morisset, et al. "Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Hematological Malignancies: Factors Impacting Its Occurrence and Treatment Options for a Better Management,." Blood 118, no. 21 (2011): 4093. http://dx.doi.org/10.1182/blood.v118.21.4093.4093.

Full text

Abstract:

Abstract Abstract 4093 Introduction: Relapse remains a major cause of mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematological diseases. During the last decade, many improvements have been achieved in the understanding of the disease- and patient-related conditions in order to obtain the optimal allogeneic effect but the relapse is still representative which leaded to the development of different chemo- and immuno-therapy strategies. Aims: To evaluate at a first time the different pre- and post-transplantation factors impacting the relapse o

APA, Harvard, Vancouver, ISO, and other styles

34

Luu, Huong, Gerald Spotts, Hartwig Gajek, et al. "ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin- Free Method] Post-Authorization Safety Surveillance (PASS): Safety and Efficacy Following Product Switch in Routine Clinical Practice." Blood 112, no. 11 (2008): 3375. http://dx.doi.org/10.1182/blood.v112.11.3375.3375.

Full text

Abstract:

Abstract A prospective, non-interventional Post-Authorization Safety Surveillance (PASS) program was initiated in 2004 to document ADVATE safety and efficacy in routine clinical practice. More than 900 subjects newly prescribed ADVATE have been enrolled in the US, EU and Japan alone. Herein, we present final US and interim EU results comprising 506 treated subjects, 451 of which have completed the 1-year observation period and 20 ongoing. Age cohorts were as follows: 27 neonates/infants (0-<2 years), 128 children (2-<12 years), 54 adolescents (12-<16 years), and 285 adults (≥16 years)

APA, Harvard, Vancouver, ISO, and other styles

35

Michalowsky, Bernhard, Iris Blotenberg, Moritz Platen, et al. "Clinical Outcomes and Cost-Effectiveness of Collaborative Dementia Care." JAMA Network Open 7, no. 7 (2024): e2419282. http://dx.doi.org/10.1001/jamanetworkopen.2024.19282.

Full text

Abstract:

ImportanceLong-term evidence for the effectiveness and cost-effectiveness of collaborative dementia care management (CDCM) is lacking.ObjectiveTo evaluate whether 6 months of CDCM is associated with improved patient clinical outcomes and caregiver burden and is cost-effective compared with usual care over 36 months.Design, Setting, and ParticipantsThis was a prespecified secondary analysis of a general practitioner (GP)–based, cluster randomized, 2-arm clinical trial conducted in Germany from January 1, 2012, to December 31, 2014, with follow-up until March 31, 2018. Participants were aged 70

APA, Harvard, Vancouver, ISO, and other styles

36

Bauman, Glenn, Mohammed Rashid, Deanna L. Langer, et al. "A prospective provincial registry of PSMA PET CT for recurrent prostate cancer (PREP): Results for 4135 men." Journal of Clinical Oncology 43, no. 5_suppl (2025): 35. https://doi.org/10.1200/jco.2025.43.5_suppl.35.

Full text

Abstract:

35 Background: PREP was initiated in Ontario to provide access and characterize performance of PSMA PET CT among men with recurrent prostate cancer after primary definitive treatment (RP or RT). Methods: Between 03/18 and 09/22, 4135 men were accrued. Men were enrolled and imaged with 18F-DCFPyL at 1 of 6 participating sites within 1 of 6 clinical cohorts. Standardized reports delineated sites of recurrence and post PET management changes. Linkage to provincial databases allowed estimation of overall survival and utilization of salvage radiotherapy after PET. Results: Median follow-up was 1.8

APA, Harvard, Vancouver, ISO, and other styles

37

Wood, Henry, Lauren Jamieson, Charles Manogaran, et al. "Correlation between the Integrated MDS Flow Cytometry Score and Genomic Abnormalities - a Single Centre Analysis from King's College Hospital." Blood 144, Supplement 1 (2024): 6751. https://doi.org/10.1182/blood-2024-211268.

Full text

Abstract:

Myelodysplastic syndromes (MDS) are diagnosed based on peripheral cytopenias, morphological dysplasia and recurrent genomic abnormalities. Gene variants are found in approximately 90% of cases and cytogenetic abnormalities in 50% (Arber et al, 2022). Genomic abnormalities are key to diagnosis and prognosis (Bernard et al, 2022). The European Leukemia Net international MDS flow cytometry working group has recommended an integrated flow cytometry score (iFS) to support diagnosis of MDS (Oelshlaegel et al 2021; van de Loosdrecht et al, 2021). The score identifies three categories based on the num

APA, Harvard, Vancouver, ISO, and other styles

38

Sabatier, Magalie, Joeska Husny, Marine Nicolas, Stèphane Dubascoux, Mary Bodis, and Ray Glahn. "Solubility and Impact of Ascorbic Acid on the in vitro Bioavailability of Two Casein-Based Iron Fortificants from Reconstituted Milk." Current Developments in Nutrition 4, Supplement_2 (2020): 1836. http://dx.doi.org/10.1093/cdn/nzaa067_063.

Full text

Abstract:

Abstract Objectives The two objectives were 1) to evaluate the solubility of two iron casein complexes (ICCs) under a condition mimicking gastric pH, 2) to evaluate the impact of ascorbic acid (AA) on the in vitro iron absorption of ICCs after incorporation in reconstituted whole milk powder. Methods The in vitro solubility was determined over time after addition of diluted HCl (pH 1.7), ultracentrifugation and measurement of iron appearing in the supernatant by ICP-OES (n = 2). The impact of AA on iron uptake from the Fe compounds in reconstituted milk was determined using the in vitro digest

APA, Harvard, Vancouver, ISO, and other styles

39

Suttorp, Meinolf, Ralf Knoefler, Hélène Deutsch, et al. "High Platelet Counts, Thrombosis, Bleeding Signs, and Acquired Von Willebrand Syndrome at Diagnosis of Pediatric Chronic Myeloid Leukemia." Blood 134, Supplement_1 (2019): 4152. http://dx.doi.org/10.1182/blood-2019-123343.

Full text

Abstract:

Background: At diagnosis of chronic myeloid leukemia (CML) patients (pats) may present with elevated platelets (PLT) counts. Generally, high PLT counts may result in thrombosis and/or bleeding complications, the latter being due to binding of von Willebrand factor (VWF) multimers to platelets. Pediatric CML is very rare (Hijiya N, Suttorp M 2019; Blood 33:2374-2384) and no systematic investigation on clinical complications of elevated PLT counts has so far been reported. Methods: Data on PLT counts and associated thrombo-hemorrhagic complications were retrospectively analyzed in newly diagnose

APA, Harvard, Vancouver, ISO, and other styles

40

Castrejon, I., J. Molina Collada, C. Perez-Garcia, et al. "POS1439 CANCER IN PATIENTS WITH RHEUMATIC DISEASES EXPOSED TO DIFFERENT BIOLOGIC AND TARGETED SYNTHETIC DMARDS IN REAL-WORLD CLINICAL PRACTICE: DATA FROM A MULTICENTER REGISTER." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1063. http://dx.doi.org/10.1136/annrheumdis-2022-eular.3834.

Full text

Abstract:

BackgroundExtensive evidence has confirmed no increased risk of cancer associated to either conventional synthetic DMARDs or anti-TNF in patients with rheumatic diseases. The risk of cancer in biologic (bDMARDs) different to anti-TNF and targeted synthetic (tsDMARDs) is considerably less investigated. As new therapies are emerging, more data in real-world registries are needed to confirm safety in other treatment groups.ObjectivesTo compare the risk of cancer of tsDMARDs and other bDMARDs versus anti-TNF in patients with rheumatic diseases.MethodsData of patients enrolled in BIOBADASER 3.0 up

APA, Harvard, Vancouver, ISO, and other styles

41

Rubalcava, Luis Felipe Felipe, Gabriela Cesarman-Maus, and Ana Florencia Ramirez-Ibarguen. "A Latin-American Cancer Center Experience in the Treatment of Hodgkin's Lymphoma during a Drug Shortage." Blood 138, Supplement 1 (2021): 1919. http://dx.doi.org/10.1182/blood-2021-153608.

Full text

Abstract:

Abstract The treatment of Hodgkin's lymphoma has been characterized by a story of success with the use tried-and-true protocols. During the second half of 2019 to the first-half of the 2021 the Mexican health system experienced a shortage of drugs, which compromised the possibility of using in most of the common protocols for this cancer: ABVD, BEACOPP, IGEV, ESHAP, DHAP, GEMOX. Clinician had option of using a common protocol with incomplete doses or applying an alternative complete CHOEP protocol, which has been used with some success in exploratory studies [1,2]. For 12 months, we treated a

APA, Harvard, Vancouver, ISO, and other styles

42

Bolek, E. C., E. Bilgin, G. K. Yardimci, et al. "AB0745 REAL-LIFE EXPERIENCE FOR SECUKINUMAB IN PSORIATIC ARTHRITIS FROM HURBio-PsA DATABASE." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1669–70. http://dx.doi.org/10.1136/annrheumdis-2020-eular.6533.

Full text

Abstract:

Background:Biologic disease modifying anti-rheumatic drugs (bDMARD) are revolutionary treatment options for management of inflammatory arthritis. Secukinumab (SEC), anti-interleukin-17A monoclonal antibody, is a new alternative choice to anti-TNFs and IL-12/23 blocking agents in the therapy of psoriatic arthritis (PsA). In Turkey, government health insurance system covers secukinumab for at bDMARD-refractory PsA patients.Objectives:In this study, analyzing of parameters that related with effectiveness and drug survival rates for patients using SEC from Hacettepe University Rheumatology Biologi

APA, Harvard, Vancouver, ISO, and other styles

43

Desai, Sanjal H., Reid W. Merryman, Harsh Shah, et al. "PD-1 Blockade before Autologous Stem Cell Transplantation Improves Outcomes in Relapsed/Refractory Classic Hodgkin Lymphoma: Results from a Multicenter Cohort." Blood 142, Supplement 1 (2023): 182. http://dx.doi.org/10.1182/blood-2023-179573.

Full text

Abstract:

Introduction: Single arm studies incorporating PD-1 blockade and/or brentuximab vedotin (BV) to salvage regimen have produced encouraging results in transplant-eligible relapsed/refractory classic Hodgkin lymphoma (R/R cHL) and are increasingly used in practice. As prospective randomized studies comparing PD1 based salvage to other salvage regimens are lacking, we conducted a retrospective study comparing post-transplant outcomes of R/R cHL patients who received PD1-based regimen and other novel and conventional regimen. Methods: Consecutive adult patients with R/R cHL who received salvage the

APA, Harvard, Vancouver, ISO, and other styles

44

Cohen, S. B., H. Schulze-Koops, J. Pope, et al. "POS0827 CLINICAL OUTCOMES OF PATIENTS WITH RHEUMATOID ARTHRITIS WHO DISCONTINUED TOFACITINIB OR TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM ORAL SURVEILLANCE." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 710–11. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2670.

Full text

Abstract:

BackgroundSwitching or discontinuing therapy may occur in patients (pts) with rheumatoid arthritis (RA) with an inadequate response/intolerance to treatment. In ORAL Surveillance, a post-authorisation safety study of tofacitinib vs tumour necrosis factor inhibitors (TNFi) in pts with RA despite methotrexate aged ≥50 years with ≥1 additional cardiovascular risk factor,[1]pts could discontinue the assigned study drug and switch to local standard of care (SOC) treatment and, in contrast to previous randomised controlled trials, were encouraged to remain in the study.ObjectivesTo assess efficacy/s

APA, Harvard, Vancouver, ISO, and other styles

45

Ulyanova, Tatiana, Ena R. Banerjee, Gregory V. Priestley, Linda Scott, and Thalia Papayannopoulou. "Migration Defects of Leukocytes from Alpha4 or Beta2 Integrin-Deficient Mice during Aseptic Peritonitis." Blood 104, no. 11 (2004): 2387. http://dx.doi.org/10.1182/blood.v104.11.2387.2387.

Full text

Abstract:

Abstract Leukocyte migration to the inflammatory sites involves a dynamic and coordinated sequence of adhesion/ migration events, in which the α4 and β2 integrins in leukocytes play critical roles. In a model of aseptic peritonitis, normal mice respond with an initial influx of neutrophils followed by later recruitment of mononuclear cells. Previous studies used antibodies to inhibit α4 integrins in this model and provided only early observations (up to 24 hrs). Events at later stages were not addressed. To clarify the role of α4 integrins in this process, we induced aseptic peritonitis in α4-

APA, Harvard, Vancouver, ISO, and other styles

46

Kerrich, R. "Carbon-isotope systematics of Archean Au–Ag vein deposits in the Superior Province." Canadian Journal of Earth Sciences 27, no. 1 (1990): 40–56. http://dx.doi.org/10.1139/e90-004.

Full text

Abstract:

Abundant carbonate is a characteristic feature of most Archean mesothermal Au–Ag vein deposits, but the source of the C is controversial. For Superior Province deposits collectively, the maximum variation of average δ13C values is from −9.0 ± 0.7‰ (1σ, n = 19; Darius) to −0.6 ± 1.6‰ (1σ, n = 7; Cochenour–Willians), and limiting δ13C values are−13.6 and + 1.3‰. At the deposit scale, Fe dolomites in nongraphitic lithologies are for the most part isotopically uniform, where δ13C = −3.4 ± 0.4 (1σ) (Hollinger), −3.2 ± 0.3 (McIntyre), −4.7 ± 1.7 (Dome), −2.8 ± 0.6 (Buffalo Ankerite), −3.6 ± 0.5 (Mac

APA, Harvard, Vancouver, ISO, and other styles

47

Brun, M. K., G. L. Goll, K. K. Jørgensen, et al. "OP0301 RISK FACTORS FOR ANTI-INFLIXIMAB ANTIBODY FORMATION: RESULTS FROM THE RANDOMISED CONTROLLED NOR-DRUM A TRIAL." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 185.2–185. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1380.

Full text

Abstract:

Background:Immunogenicity is related to loss of efficacy and safety to TNFα inhibitors and is frequently observed early in the treatment course. The highest rate of anti-drug antibody (ADAb) formation has been reported for infliximab (IFX). 1 Knowledge about risk factors for immunogenicity might contribute to better handling of this problem in clinical practice.Objectives:To identify risk factors for ADAb formation during the early phase of IFX treatment.Methods:411 patients with immune-mediated inflammatory diseases (84 rheumatoid arthritis (RA), 119 spondyloarthritis (SpA), 45 psoriatic arth

APA, Harvard, Vancouver, ISO, and other styles

48

Remy, Katya, Chase Alston, Elyse Gonzales, et al. "Targeted Reinnervation During Gender-Affirming Mastectomy and Restoration of Sensation." JAMA Network Open 7, no. 11 (2024): e2446782. http://dx.doi.org/10.1001/jamanetworkopen.2024.46782.

Full text

Abstract:

ImportanceDuring gender-affirming mastectomy, nerves are transected, resulting in sensory loss. Nerve preservation using targeted nipple-areola complex (NAC) reinnervation (TNR) may restore sensation.ObjectiveTo determine the quantitative and patient-reported sensory outcomes of TNR.Design, Setting, and ParticipantsProspective matched cohort study of patients undergoing gender-affirming mastectomy from August 2021 to December 2022 at Weill Cornell Medicine and Massachusetts General Hospital. Data were analyzed from January to March 2023.ExposurePatients who underwent TNR and matched patients w

APA, Harvard, Vancouver, ISO, and other styles

49

Domínguez-Casas, L. C., P. Rodriguez Cundin, T. Dierssen-Sotos, et al. "AB0279 HERPES ZOSTER IN RHEUMATOID ARTHRITIS. PROSPECTIVE SINGLE UNIVERSITY CENTER STUDY." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1265.2–1266. http://dx.doi.org/10.1136/annrheumdis-2022-eular.3057.

Full text

Abstract:

BackgroundPatients with Rheumatoid arthritis (RA) have an increased risk of infections due to the disease itself, and/or immunosuppressive therapy. The risk of herpes zoster (HZ) including disseminated HZ is also increased(1)ObjectivesIn an unselected series of RA patientswe assessa)prevalence, b)general features and c) predictive factors of HZ.MethodsStudy of 393 RA patients included in the prospective vaccination program of the Preventive Medicine and Rheumatology department of a University hospital, from October 2011 to October 2016. The minimum follow-up was of 12 months; therefore, it was

APA, Harvard, Vancouver, ISO, and other styles

50

Fenk, Roland, Florian Neubauer, Ingmar Bruns, et al. "Secondary Primary Malignancies in Patients with Multiple Myeloma Treated with High-Dose Chemotherapy and Autologous Blood Stem Cell Transplantation,." Blood 118, no. 21 (2011): 4087. http://dx.doi.org/10.1182/blood.v118.21.4087.4087.

Full text

Abstract:

Abstract Abstract 4087 Introduction: Secondary primary malignancies (SPM) are an emerging issue in patients with multiple myeloma (MM) since the French IFM 99–02 trial has been closed as a consequence of a higher incidence of SPM in patients who had received lenalidomide as maintenance treatment compared to the patients in the placebo arm. Methods: To evaluate the incidence of SPM in the group of patients, who were treated with high-dose therapy (HDT) followed by autologous peripheral blood stem cell transplantation (PBSCT), we retrospectively looked at a homogeneous group of 313 consecutive p

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!